There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.
Introduction
A reciprocal translocation between the long arms of chromosome 9 and chromosome 22 [t(9;22)(q34;q1.1)] results in the formation of a fusion hybrid gene (BCR-ABL1) that encodes proteins with a constitutively activated tyrosine kinase activity [1, 2] . The proteins are leukemogenic and cause either chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL, so-called Philadelphia chromosome-positive ALL) [1, 2] . The site of the breakpoint in the ABL1 gene (chromosome 9) "can occur anywhere within a > 300-kb segment at the 5' end of the gene, either upstream of the first alternative intron Ib, between exons Ib and Ia, or downstream of exon Ia" [1] . The site of the breakpoint in the BCR gene (chromosome 22) can occur in different regions "within a 5.8-kb region known as the major breakpoint cluster region (M-bcr), spanning 5 exons historically named b1 to b5, now known to be exon 12 to 16 of the bcr gene" [1] . In more than 90% of patients, the transcripts are e13a2 (also known as b2a2) or e14a2 (also known as b3a2), which can be found either alone or together. However, in some patients other types of transcripts can be found, that are defined as "rare" or "atypical" [1, 2] . The frequency of the different molecular types of CML has never been systematically and thoroughly investigated. The reported proportion of e13a2 ranged between 34.4% and 42.5% in clinical studies, between 33.9% and 49.4% in international, national, or regional registries, and between 20.0% and 94.6% in monocentric studies (Table 1S ). The reported proportion of patients co-expressing the two M-bcr transcripts (e14a2 and e13a2) ranged between 1.1% and 26.9% (Table 1S ). The proportion of atypical, rare transcripts was rarely reported, ranging between 0.9% and 13.0% (Table 1S ).
The translation of each different RNA transcript results in different protein tyrosine kinases that can potentially affect the biologic characteristics of the disease and the response to treatment. For this reason, we planned a worldwide overview of the prevalence of BCR-ABL1 transcript types.
ABL1-positive CML, who were newly diagnosed over a defined period of time, i.e., between 1990 and 2016. The protocol was approved by the Ethic Committee (EC) of the S.Orsola-Malpighi University Hospital, Bologna, and by the EC of the participating institutions, as required by national rules.
The sources of all the data were institutional-clinical or laboratory-databases. The aim of the study was to investigate if the proportion of different transcript types was associated with gender, age, and the region where patients were living. Accordingly, calculations and comparisons were made for gender (females vs. males), for different age groups (by 20-year intervals), and for continents, so as to understand if the distribution of the type of the transcript was constant worldwide or could vary on geographic bases.
The data were tabulated and analyzed according to the original transcript identification, as it was reported in the respective databases, as e13a2, e14a2, e14a2/e13a2, or other transcript types, although it is acknowledged that any patients may express more than one transcript, due to alternative mechanisms of splicing [1, 2, 31] . The transcript that is prevalent is used to define the transcript type of the patient, and, regrettably, there is no agreement on how reporting the other transcripts that can be detected in smaller amounts, depending on the sensitivity of PCR. For all the calculations, we have pooled the patients where a coexpression of both M-bcr transcripts (e14a2/e13a2) was reported with the patients who were reported to express only e14a2. In such cases, the breakpoint must be located downstream to exon 14, because an e14a2 can also make an e13a2, but an e13a2 does not contain exon 14. Some patients with the simultaneous expression of an M-bcr and an m-bcr (e1a2) transcript were also reported by 11 centers. Here again, such co-expression is explained by alternative splicings [1, 2, [31] [32] [33] . Therefore, none of the patients with a reported simultaneous expression of an M-bcr and an mbcr transcript was classified as a case of an atypical or rare transcript type.
Statistics
For descriptive analyses, raw, unadjusted proportions are stated. To improve comparability of the prevalence of e13a2 between groups, adjusted odds ratios (ORs), together with their 95% confidence intervals (95% CIs), were estimated by multiple logistic regression. The adjustment was done by including gender, age group, and continent in the regression model. Regarding the analyses of atypical transcripts, continent was not included in the logistic model, because information was only based on Asia and Europe. The significance level of the two-sided P-values was 0.05. Since all analyses are descriptive and explorative, P-values were not adjusted for multiple comparisons. Analyses were done with SAS version 9.4.
Results
A summary of the number of patients who were collected, and detailed information on their distribution by continent, by gender, and by age is shown in Table 2S . The total number of reported patients was 45503. Females were 48% of the total in Africa, 43% in Australia, Europe, and South America, and only 38% in Asia. Excluding the childhood registry, the male to female ratio (M:F) was 1.33 overall, ranging from 1.08 for Africa to 1.64 for Asia (Table 3S ). Of note, the M:F ratio decreased with age, down to 1.10 for the very elderly (Table 3S ). Between continents, patient distributions by age (Fig. 1) were uneven, since the proportion of children and adolescents ranged between 1.3% for Africa and 6.6% for Asia, while the proportion of elderly patients (≥ 60 years old) ranged between 13.1% for Asia and 41.8% for Europe (Table 2S ). The majority of the data of young patients (0-19 and 20-39 years old) was contributed by Asia and Europe (see also Table 3S ), while Europe contributed more than 50% of the 40-59 years old patients, and more than 80% of the patients ≥ 80 years old. The simultaneous expression of both M-bcr transcripts (e14a2/e13a2) was reported in 7.6% of the patients overall, ranging from 2.4% for Asia to 18.7% for Australia (Table 4S) .
M-bcr transcripts
The proportion of patients who were reported to express only the e13a2 transcript was 37.9% overall, but was different by gender, by age, and by continent (Table 1) . By gender, the proportion was 39.2% for males and 36.2% for females. The age-and continent-adjusted OR of males versus females was 1.149 (95% CI: 1.106-1.194, P < 0.0001). Regarding age, the raw proportions expressing In Africa and in Asia, the age was shifted to the left, while in Europe it was shifted to the right. To account for these uneven distributions, all the calculations of the odds ratios were adjusted for age Table 1 Number and proportion of patients with e13a2, by continent, by gender, and by age Continent (gender) 0-19 years, n (%) 20-39 years, n (%) 40-59 years, n (%) 60-79 years, n (%) > = 80 years, n (%) Total (%)
Africa ( By gender, the proportion was 39.2% for males and 36.2% for females, the age-and continent-adjusted odds ratio of males versus females being 1.149 (95% confidence interval: 1.106-1.194, P < 0.0001) only the e13a2 transcript were similar in the first two age groups (39.6% and 39.9%, respectively), but decreased in the subsequent age groups to 38.7%, 35.6%, and 31.6%, respectively ( Table 2) . With reference to the 0-19 years old, the ORs of the 60-79 years old patients (OR: 0.775, 95% CI: 0.690-0.871, P < 0.0001) and of the patients ≥ 80 years (OR: 0.647, 95% CI: 0.560-0.749, P < 0.0001) were significantly lower. This pattern of decrease was found in males as well as in females (Fig. 2a) . As compared with South America, the proportion of patients with e13a2 was 33.2% in Asia, 35.4% in Australia, 37.6% in Europe, and 44.6% in Africa (P = 0.0001, 0.0308, 0.0773, and 0.0001, respectively) ( Table 5S ). The data from children and adolescents are listed in Table 3 , distinguishing between children (0-9 years old) and adolescents (10-19 years old), and separately for the data from the International Childhood CML Registry and all other sources. The proportion with e13a2, overall, was 38.7%, being 38.2% in males and 39.4% in females. No further comparisons were made because of low patient numbers and different sources.
Atypical, rare BCR-ABL1 transcripts
Thirteen different atypical transcripts were reported in 603 of 34561 patients (Table 4) . Sixty-three additional cases of atypical transcripts were reported, where the exact transcript type was not identified, totaling to 666 cases and a proportion of 1.93%. The distribution of the 666 cases of atypical transcripts, overall and by gender, is shown in Fig. 3 . Overall, all these transcripts were more frequent in females than in males: 2.27% versus 1.69% (OR 1.352, 95% CI: 1.159-1.576, P = 0.0001). More frequent transcripts were e1a2, e19a2, e13a3, and e14a3. e1a2 was twice more frequent in females than in males: 1.33% versus Adjusted ORs were estimated from multiple logistic regression with continent, age group, and gender as common explanatory variables. The differences among age groups were all significant, with the exception of the first age group (0-19) as compared with the age groups 20-39 and 40-59 years Fig. 2 a Proportion of e13a2 by age, in males and females; data on all continents were combined. Differences between age groups were found in both genders. Bars indicate the 95% confidence interval around a proportion. b Proportion of atypical, rare transcripts by age, in males and females; data on all continents were combined. Differences between age groups were found in both genders. Bars indicate the 95% confidence interval around a proportion 0.62% (OR 2.172, 95% CI: 1.731-2.724, P < 0.0001), and was present in 58.6% of males versus 36.5% of females with any atypical transcript. Less frequent transcripts were e1a3, e6a2, and e8a2. Some further, very rare transcripts (e1a1, e8a1, e8a3, e15a2, e23a1) were reported in only six patients. These transcripts were not clear exon/exon fusions, and some had additional nucleotides inserted in the chimeric mRNA that may or may not have maintained the reading frame. The proportion of atypical transcripts was similar in the first three age groups, ranging from 1.79% in patients 0-19 years old to 1.58% in patients 40-59 years old and increasing in the elderly up to 3.84% for patients ≥ 80 years old ( Table 5 ). The increase with higher age was found in both genders (Fig. 2b) . For children (0-9 years old) and children and adolescents (10-19 years old), the proportion of patients with atypical transcripts was calculated separately for the data collected by the International Childhood CML Registry and the data collected from all other sources (Table 3) . Overall, for children, the proportion of atypical transcripts was 3.25%. For children and adolescents combined, the proportion was 2.11%. No further comparisons were made because of low patient numbers and different sources of the data.
Discussion
The results of this international overview must be interpreted with caution, taking into account how the data were collected. The collection was retrospective, from the clinical and laboratory database of the centers that were invited. Care was taken to ensure the quality of the data, but it is acknowledged that the basis of the review was by necessity so large that a few errors or inconsistencies may not have been avoided. Thus, the data cannot provide the exact prevalence of all the transcripts. However, it is justifiable to assume that at least the M-bcr transcripts were reported independently of their parameter value, may it have been Note that the Childhood registry reported only on patients who had been referred to Children hospitals, while all the other sources reported mainly on adults, and on children data only occasionally Numbers and percentages, overall and by gender. Other transcripts were reported as e1a1, e8a1, e8a3, e15a2, and e23a1 -not all are clear exon/exon fusions. Some of them had additional nucleotides inserted in the chimeric mRNA that may or may not have maintained the reading frame e13a2 or e14a2 or both. Accordingly, we can at least report an estimate of the "prevalence" of e13a2 in relation to our sample. This study was planned with the aim of collecting as many data as possible from as many countries as possible, because the goal was to provide an overview of the prevalence of different transcripts, to analyze if it is related with gender and age, and also if the prevalence is constant worldwide or varies from region to region. The full achievement of these goals was limited because several countries could not contribute data, and, regrettably, no data could be collected from North and Central Americas.
The first aim was to calculate the proportion of the two M-bcr transcripts, that was 37.9% for e13a2, and, accordingly, 62.1% for e14a2 + e14a2/e13a2. Even taking into account the limitations due to the lacking information from many regions, this overview provides the best available estimates of the true prevalence of the two M-bcr transcripts, worldwide.
It was interesting and important to find that the M-bcr transcript proportions differed by gender and age, and also by continent. These differences were previously unknown or unrecognized. Differences by gender and age are wellknown to affect the incidence of many cancers, including CML, that is more frequent in males and in the elderly. Now, we found that age and gender affect also the distribution of the M-bcr transcript types. The differences by continent cannot have technical explanations, because they were found across gender and age, and because "continents" included different countries and different laboratories. Moreover they cannot depend on the definition of the transcript, because the patients who were reported to coexpress both M-bcr transcripts were always pooled together with the patients who were reported to express only e14a2. Fig. 3 Distribution of the transcript type in the 666 patients with atypical, rare transcripts, overall, and by gender. The proportion of e1a2 transcript, coding for P190, was 47.3% of all transcripts, 58.6% in females (F) and 36.5% in males (M). The proportion of other transcripts was as follows: e6a2 3.8% overall, 0.9% in females and 6.4% in males; e8a2 2.7% overall, 2.5% in females and 2.9% in males; e13a3 9.0% overall, 4.9% in females and 12.9% males; e14a3 9.6% overall, 6.5% in females and 12.6% in males; e19a2, coding for P230, 16.4% overall, 17.0 % in females and 15.8% in males. Overall, atypical, rare transcripts were more frequent in females than in males (OR 1.352, 95% CI: 1.159-1.576, P = 0.0001). NS (transcript) not specified Adjusted ORs were estimated from multiple logistic regression with age group and gender as common explanatory variables. As almost only European and Asian data were available, the variable "continent" was not considered. The proportion was fairly constant in the first three age groups but increased significantly in the elderly
Since every continent includes regions with geographic and ethnic differences, and since data collection was far from covering all continents, these explicit proportions must be considered with caution and do not provide reliable estimates for a certain combination of continent, age group, or gender in an epidemiologic sense. However, they suggest that the distribution of BCR-ABL1 transcript types is not the same worldwide. In summary, it was found that the proportion of e13a2 was higher in males than in females, that it decreased with age for both genders, and that it has geographic variations. Whether the type of the M-bcr transcript affects the biological characteristics of the disease and the response to treatment was a matter of a debate that begun many years ago [34] , in the era of chemotherapy and interferon alfa [4, 5, 9] . A difference in platelet count (lower in e13a2 patients) and in leukocyte count (higher in e13a2 patients) had already been reported [1-3, 11, 19, 22] . After the introduction of tyrosine kinase inhibitors (TKI), it was found that e13a2 was associated with a lower rate of complete cytogenetic response (CCyR) and a longer time to CCyR [16] , and with a lower rate of major molecular response (MMR) and a longer time to MMR in imatinibtreated patients [3, 4, 19, 20, 35] , and also in nilotinibtreated patients [7] , as well as with a lower rate of deep MR (MR 4.0) [4, 35] . Three studies of 1494, 481, and 559 imatinib-treated patients reported an inferior overall survival, leukemia-related survival, progression-free survival, and transformation-free survival in e13a2 patients, respectively [14, 19, 35] . Few studies of treatment-free remission (TFR), that is nowadays the most important goal of treatment, have reported or analyzed transcript data. In a study of de-escalation of treatment [36] , it was found that the molecular relapse rate was twice as high in e13a2 patients as in e14a2 patients. The e13a2 transcript was reported to have a significant adverse impact on the achievement of a sustained deep molecular response and on the maintenance of TFR [37] . In a preliminary analysis of 249 patients who had achieved a deep molecular response and had discontinued treatment, only 62 (25%) were found to have the e13a2 transcript, less than expected from a random distribution, thus supporting the hypothesis that e13a2 patients achieve a deep molecular response less frequently (Fava C, personal communication). Moreover, female sex and older age, that are both associated with a lower incidence of e13a2, were reported to predict stable undetectable molecular response and TFR rates, respectively [38, 39] . Of interest, in a study of BCR-ABL1+ acute lymphoblastic leukemia (ALL) [40] it was found that out of a total of 15 P210 patients, 13 (86%) had the e13a2 transcript, suggesting that the protein encoded by e13a2 may have different biological properties. Different transcripts result into slightly different proteins, but could also result in different cellular amounts of the leukemogenic proteins, and in different sensitivity to TKIs. Moreover, since the proteins that are encoded by the two transcripts differ in 25 amino acids at the fusion junction of Bcr and Abl1, the two proteins may have a different immunogenicity, and may be recognized by different antibodies or different lymphocytes or natural killer cells, thus affecting the immunological control of minimal residual disease [41] [42] [43] [44] . Few studies have reported on a relationship between immunogenicity and transcript type and it is of interest that they all focused on the e14a2 transcript. Patients with e14a2, but not e13a2, were reported to produce IFNγ in response to stimulation with Ph+ monocytederived dendritic cells [41] . An immune response and a clinical benefit were reported in 11 of 16 e14a2 patients who were vaccinated with a peptidic vaccine derived from the sequence p210-e14a2 [42] . Nineteen e14a2 imatinibtreated patients were vaccinated with Bcr-Abl1 peptides spanning the e14a2 fusion junction, and 14 of 19 developed T-cell responses to those peptides [43] . In a pilot study of vaccination with autologous non-irradiated dendritic cells, T-cells recognizing leukemia-associated antigens became detectable in three of ten patients, and all three had the e14a2 transcript [44] .
The so-called atypical or rare transcripts (all transcripts but e13a2 and e14a2) were detected and reported since many years [1, 2] , with focus on a shorter transcript, e1a2 [3, 19, 24, [45] [46] [47] [48] [49] , and on a longer transcript, e19a2 [1-3, 19, 24] . The frequency of e1a2 reported so far ranged between 0.26% and 3.31% [3, 24, [45] [46] [47] [48] [49] [50] . In this overview, it was found that the proportion of e1a2 was 0.91%, twice higher in females than in males (1.33% vs. 0.62%). e1a2 is the transcript coding for P190, that has different, peculiar, biologic characteristics [51] [52] [53] [54] [55] [56] , and causes BCR-ABL1+ ALL, that is more frequent in the elderly. Several casereports have suggested that in patients with CML, e1a2 is associated with an inferior response to TKIs and an inferior outcome [45] [46] [47] [48] 57] . Opposed to what was observed for e1a2, it was found that the proportion of the "a3" variants (where the transcript does not contain "a2") was higher in males than in females. The biological characteristics of the "a3" variants, lacking the a2 exon, are not clear, because the partial deletion of the SH3 domain that is encoded by the a2 exon may result either in higher levels of activation and leukemogenicity, or, on the opposite, might reduce signaling and leukemogenicity [58, 59] . e19a2, coding for P230, has been associated with a particular type of chronic neutrophilic leukemia [1-3, 54, 55] . Precautionary, all patients with a rare, atypical transcript should be considered as having atypical forms of CML with different sensitivity to treatment and different outcomes.
In conclusion, this overview showed that the distribution of the different transcript types is not likely to be ruled by chance. The data should be considered with caution, only as a best approximate to the true transcript frequency, since the overview could not cover homogeneously all continents, and the data of rare transcripts were collected mainly from Asia and Europe and were not available across all centers. Epidemiologic studies are requested to clarify geographic or ethnic differences. The study was designed to evaluate only the distribution of transcript types, and its relationship with gender and age, and cannot allow speculation on the mechanisms underlying these relationships. However, since a relationship with gender and age has been established, and since different transcripts may affect the biology of the disease and the rates of response, of outcome, and particularly of TFR, it is suggested that the transcript is a variable that may help refining the strategies of treatment, may influence the outcome, and should be taken into consideration in all studies of CML. The differences shown in this study are small, but even small differences may be important in a disease where current treatment is so successful that the survival of CML patients is already aligned with the survival of non-leukemic people [60, 61] , so that the ambition is to achieve a TFR.
